Lates News

date
17/11/2026
On November 16, Novo Nordisk announced the primary results of the STEP Young Phase 3 clinical trial. The trial was designed to evaluate, on the basis of caloric restriction and increased physical activity, the investigational once-weekly semaglutide injection at maximum doses of 1.7 mg or 2.4 mg based on baseline body weight, in patients aged 6 to